questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Phosphatidylinositol 3-kinases
Phosphatidylinositol-4-phosphate 3-kinase
Phosphatidylinositol-4-phosphate 3-kinase : Questions médicales fréquentes
Termes MeSH sélectionnés :
Attention Deficit Disorder with Hyperactivity
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Phosphatidylinositol-4-phosphate 3-kinase : Questions médicales les plus fréquentes",
"headline": "Phosphatidylinositol-4-phosphate 3-kinase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Phosphatidylinositol-4-phosphate 3-kinase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-02",
"dateModified": "2025-02-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol-4-phosphate 3-kinase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phosphatidylinositol 3-kinases",
"url": "https://questionsmedicales.fr/mesh/D019869",
"about": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol 3-kinases",
"code": {
"@type": "MedicalCode",
"code": "D019869",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.556"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Phosphatidylinositol 3-kinases de classe I",
"alternateName": "Class I Phosphatidylinositol 3-Kinases",
"url": "https://questionsmedicales.fr/mesh/D058534",
"about": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol 3-kinases de classe I",
"code": {
"@type": "MedicalCode",
"code": "D058534",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.556.200.100"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Phosphatidylinositol 3-kinase de classe Ia",
"alternateName": "Class Ia Phosphatidylinositol 3-Kinase",
"url": "https://questionsmedicales.fr/mesh/D058543",
"about": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol 3-kinase de classe Ia",
"code": {
"@type": "MedicalCode",
"code": "D058543",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.556.200.100.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phosphatidylinositol 3-kinases de classe Ib",
"alternateName": "Class Ib Phosphatidylinositol 3-Kinase",
"url": "https://questionsmedicales.fr/mesh/D058544",
"about": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol 3-kinases de classe Ib",
"code": {
"@type": "MedicalCode",
"code": "D058544",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.556.200.100.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Phosphatidylinositol 3-kinases de classe II",
"alternateName": "Class II Phosphatidylinositol 3-Kinases",
"url": "https://questionsmedicales.fr/mesh/D058541",
"about": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol 3-kinases de classe II",
"code": {
"@type": "MedicalCode",
"code": "D058541",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.556.200.200"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol-4-phosphate 3-kinase",
"alternateName": "Phosphatidylinositol-4-Phosphate 3-Kinase",
"code": {
"@type": "MedicalCode",
"code": "D058538",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Padinjat Raghu",
"url": "https://questionsmedicales.fr/author/Padinjat%20Raghu",
"affiliation": {
"@type": "Organization",
"name": "Cellular Organization and Signaling, National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore, 560065, India. Electronic address: praghu@ncbs.res.in."
}
},
{
"@type": "Person",
"name": "Swarna Mathre",
"url": "https://questionsmedicales.fr/author/Swarna%20Mathre",
"affiliation": {
"@type": "Organization",
"name": "National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore 560065, India; Manipal Academy of Higher Education, Manipal, Karnataka 576104, India."
}
},
{
"@type": "Person",
"name": "Mariko Kato",
"url": "https://questionsmedicales.fr/author/Mariko%20Kato",
"affiliation": {
"@type": "Organization",
"name": "Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto, 611-0011 Japan."
}
},
{
"@type": "Person",
"name": "Tomohiko Tsuge",
"url": "https://questionsmedicales.fr/author/Tomohiko%20Tsuge",
"affiliation": {
"@type": "Organization",
"name": "Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto, 611-0011 Japan."
}
},
{
"@type": "Person",
"name": "Takashi Aoyama",
"url": "https://questionsmedicales.fr/author/Takashi%20Aoyama",
"affiliation": {
"@type": "Organization",
"name": "Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto, 611-0011 Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).",
"datePublished": "2023-03-27",
"url": "https://questionsmedicales.fr/article/36971690",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD009885.pub3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Altered somatosensory processing in adult attention deficit hyperactivity disorder.",
"datePublished": "2024-08-13",
"url": "https://questionsmedicales.fr/article/39138461",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12888-024-06002-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Parental perspectives on attention-deficit/hyperactivity disorder treatments for children.",
"datePublished": "2022-06-13",
"url": "https://questionsmedicales.fr/article/35695509",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/13591045221108836"
}
},
{
"@type": "ScholarlyArticle",
"name": "Potential Inflammatory Biomarker in Patients with Attention Deficit Hyperactivity Disorder.",
"datePublished": "2022-10-27",
"url": "https://questionsmedicales.fr/article/36361835",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms232113054"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sensory Processing in Children and Adolescents with Attention Deficit Hyperactivity Disorder.",
"datePublished": "2022-10-14",
"url": "https://questionsmedicales.fr/article/36239408",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10870547221129306"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Phosphatidylinositol 3-kinases",
"item": "https://questionsmedicales.fr/mesh/D019869"
},
{
"@type": "ListItem",
"position": 6,
"name": "Phosphatidylinositol-4-phosphate 3-kinase",
"item": "https://questionsmedicales.fr/mesh/D058538"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Phosphatidylinositol-4-phosphate 3-kinase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Comment diagnostiquer une dysfonction de PI3K ?\nQuels tests sont utilisés pour évaluer PI3K ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels symptômes peuvent indiquer un problème avec PI3K ?\nY a-t-il des marqueurs spécifiques pour PI3K ?",
"url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Quels sont les symptômes d'une activation anormale de PI3K ?\nComment PI3K affecte-t-il le métabolisme ?\nLes troubles neurologiques sont-ils liés à PI3K ?\nY a-t-il des signes cutanés associés à PI3K ?\nLes douleurs articulaires peuvent-elles être liées à PI3K ?",
"url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Peut-on prévenir les troubles liés à PI3K ?\nY a-t-il des tests de dépistage pour PI3K ?\nLes habitudes alimentaires influencent-elles PI3K ?\nL'exercice physique aide-t-il à réguler PI3K ?\nLes facteurs environnementaux affectent-ils PI3K ?",
"url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Quels traitements ciblent PI3K ?\nLes thérapies géniques peuvent-elles aider ?\nY a-t-il des effets secondaires des inhibiteurs de PI3K ?\nComment la nutrition influence-t-elle PI3K ?\nLes traitements sont-ils personnalisés pour PI3K ?",
"url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Quelles complications peuvent survenir avec PI3K ?\nLes maladies cardiovasculaires sont-elles liées à PI3K ?\nComment PI3K influence-t-il le cancer ?\nY a-t-il des risques de résistance aux traitements ?\nLes troubles métaboliques sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Quels sont les facteurs de risque pour les troubles de PI3K ?\nL'âge influence-t-il le risque lié à PI3K ?\nLe stress a-t-il un impact sur PI3K ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'alimentation influence-t-elle le risque de troubles de PI3K ?",
"url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de PI3K ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses biochimiques peuvent être utilisés pour diagnostiquer les anomalies de PI3K."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer PI3K ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'activité enzymatique et les dosages de métabolites spécifiques sont courants."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biopsies peuvent être nécessaires pour évaluer l'expression de PI3K dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec PI3K ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés comme des troubles métaboliques ou des anomalies de croissance peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour PI3K ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs moléculaires comme PIK3CA peuvent indiquer une activation anormale de PI3K."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une activation anormale de PI3K ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles métaboliques, des anomalies de croissance et des cancers."
}
},
{
"@type": "Question",
"name": "Comment PI3K affecte-t-il le métabolisme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "PI3K régule le métabolisme en influençant la signalisation de l'insuline et la lipogenèse."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés à PI3K ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements de PI3K peuvent être associés à des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à PI3K ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent apparaître, notamment dans des syndromes génétiques liés à PI3K."
}
},
{
"@type": "Question",
"name": "Les douleurs articulaires peuvent-elles être liées à PI3K ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles inflammatoires peuvent être exacerbés par des anomalies de PI3K."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés à PI3K ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et un mode de vie actif peuvent réduire les risques associés à PI3K."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests de dépistage pour PI3K ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques peuvent être recommandés pour les personnes à risque de troubles liés à PI3K."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles PI3K ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en acides gras oméga-3 peut moduler l'activité de PI3K."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à réguler PI3K ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la signalisation de PI3K et la santé métabolique."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux affectent-ils PI3K ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains toxiques peut influencer l'activité de PI3K et le risque de maladies."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent PI3K ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de PI3K sont utilisés dans le traitement de certains cancers et maladies métaboliques."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques peuvent-elles aider ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique peut corriger des mutations dans les gènes codant pour PI3K."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires des inhibiteurs de PI3K ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des troubles gastro-intestinaux et des infections."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle PI3K ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut moduler l'activité de PI3K et améliorer la santé métabolique."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés pour PI3K ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques de PI3K."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec PI3K ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers, des troubles métaboliques et des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles liées à PI3K ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies de PI3K peuvent contribuer à des maladies cardiovasculaires par des mécanismes inflammatoires."
}
},
{
"@type": "Question",
"name": "Comment PI3K influence-t-il le cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "PI3K est souvent activé dans divers cancers, favorisant la croissance tumorale et la survie cellulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de résistance aux traitements ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans PI3K peuvent entraîner une résistance aux inhibiteurs de PI3K."
}
},
{
"@type": "Question",
"name": "Les troubles métaboliques sont-ils réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains troubles métaboliques liés à PI3K peuvent être gérés par des changements de mode de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles de PI3K ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques, l'obésité et un mode de vie sédentaire."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque lié à PI3K ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de troubles liés à PI3K augmente avec l'âge en raison de l'accumulation de mutations."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur PI3K ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter la signalisation de PI3K et contribuer à des maladies."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancers ou de troubles métaboliques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le risque de troubles de PI3K ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en sucres et graisses saturées peut augmenter le risque."
}
}
]
}
]
}
Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed and treated psychiatric disorders in childhood. Typically, children and adolescents with ADHD find it difficult to...
To assess the beneficial and harmful effects of methylphenidate for children and adolescents with ADHD....
We searched CENTRAL, MEDLINE, Embase, three other databases and two trials registers up to March 2022. In addition, we checked reference lists and requested published and unpublished data from manufac...
We included all randomised clinical trials (RCTs) comparing methylphenidate versus placebo or no intervention in children and adolescents aged 18 years and younger with a diagnosis of ADHD. The search...
Two review authors independently conducted data extraction and risk of bias assessment for each trial. Six review authors including two review authors from the original publication participated in the...
We included 212 trials (16,302 participants randomised); 55 parallel-group trials (8104 participants randomised), and 156 cross-over trials (8033 participants randomised) as well as one trial with a p...
methylphenidate versus placebo or no intervention may improve teacher-rated ADHD symptoms (standardised mean difference (SMD) -0.74, 95% confidence interval (CI) -0.88 to -0.61; I² = 38%; 21 trials; 1...
methylphenidate may cause more adverse events considered non-serious versus placebo or no intervention (RR 1.23, 95% CI 1.11 to 1.37; I² = 72%; 35 trials 5342 participants; very low-certainty evidence...
The majority of our conclusions from the 2015 version of this review still apply. Our updated meta-analyses suggest that methylphenidate versus placebo or no-intervention may improve teacher-rated ADH...
Tactile sensitivity and sensory overload in ADHD are well-documented in clinical-, self-, and parent- reports, but empirical evidence is scarce and ambiguous and focuses primarily on children. Here, w...
Somatosensory evoked potential (SEP) amplitudes were measured in 27 adults with ADHD and 24 controls during four conditions (rest, stroking of the own arm, stroking of the arm by a researcher, and str...
Participants with ADHD self-reported greater tactile sensitivity and ADHD symptom severity than controls and received higher scores on the Qb-test. These values correlated with one another. ADHD parti...
We find that ADHD symptomatology and touch sensitivity are directly linked, using both self-reports and experimental measures. We also find evidence of tactile sensory overload in ADHD, and an indicat...
This study investigated parental perspectives and experiences on the evaluation and treatment process associated with attention-deficit/hyperactivity disorder (ADHD). Five hundred sixty-eight parents ...
Attention deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder that can diminish the quality of life of both children and adults in academic, occupational, and social conte...
The aim is to assess the sensory processing difficulties in children and adolescents with ADHD....
In all, 38 ADHD children of the age group 6-14 years and 34 age- and gender-matched typically developing controls were included in the study. Sensory processing was assessed on Child Sensory Profile-2...
A significantly higher sensory processing difficulties were seen in children with ADHD than typically developing controls. There were positive correlations between the scores of Child sensory profile ...
Sensory problems were common in children with ADHD and add to the functional impairments....
To investigate the association between the risk of attention-deficit/hyperactivity disorder (ADHD) and preterm birth and determine how postnatal complications in children born preterm is associated wi...
This population-based cohort study used data from the Hong Kong electronic medical records. We followed 359 614 children (48% female; 6-17 years old, mean 11 years 7 months, SD 3 years 2 months) born ...
The risk of ADHD was 4.0% in children born at term and 5.1% in children born preterm. The odds ratio for ADHD was 2.08 (95% confidence interval [CI] 1.64-2.64) for children born extremely preterm, 1.6...
Children born preterm in all subcategories, from extremely preterm to late preterm, have increased risk of ADHD. Early respiratory infection partially mediates the risk of ADHD in children born preter...
Despite advances in identifying rare and common genetic variants conferring risk for ADHD, the lack of a transcriptomic understanding of cortico-striatal brain circuitry has stymied a molecular mechan...
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders of childhood, and is often characterized by altered executive functioning. Executive function has...
Sleep disturbances may be a significant source of distress for children with neurodevelopmental disorders, and consequently also for their families. Crucially, sleep disturbances might be influenced b...
Substance use disorders (SUDs) are a considerable public health problem. Attention-deficit/hyperactivity disorder (ADHD) frequently occurs in patients with SUD. Several studies demonstrated that ADHD ...
The study aimed to explore the effect of childhood ADHD pharmacotherapy on later life's functional impairment and substance use patterns....
Treatment-seeking SUD patients with ADHD (n = 52) were recruited from various rehabilitation facilities in South Africa. Adult ADHD individuals without SUD (n = 48) were recruited from clinicians, ret...
Medicated participants (n = 59) showed lower levels of ADHD-related impairment across all functional domains (p < 0.001), compared to non-medicated participants (n = 41). They also consumed less alcoh...
Childhood ADHD pharmacotherapy might be associated with a decreased risk for substance use in adulthood and lower ADHD-related impairment. Despite study limitations, these findings underline the impor...